Craif Starts Offering New Product in “miSignal®️” Series, “Remote Cancer TestTM

 Craif Inc. (Location: Bunkyo-ku Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) starts “Remote Cancer TestTM,” a home-completed test, from 7th November. Together with the launch of Remote Cancer TestTM, the product website will be open. For further information, please visit our website ( 
 Craif will continue to take on the challenge of its vision, “realizing a society in which people can live out their natural lives”,by widely delivering new initiatives for early detection of all kinds of diseases and optimization of treatment.

■ Outline of Remote Cancer ScreeningTM
 Remote Cancer TestTM is a next-generation cancer test* that focuses on microRNAs, which play an important role in the onset, progression, and metastasis of cancer. The greatest feature of this service is that it is “easy and painless.” By simply collecting urine and sending it by post mail, you can easily check the risk of cancer without any burden. Currently, the service is available for seven types of cancer (colorectal, lung, stomach, breast, pancreatic, esophageal, and ovarian cancer). For details, please visit the website (
*Craif is the industry’s first cancer test technology that uses AI to analyze microRNAs in urine.